Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV vaccine effectiveness study among men who have sex with men in Amsterdam
2022-502224-49-00Phase 4Completed
- Sponsor
- Public Health Service of Amsterdam
- Start
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection (2 cohorts), sponsored by Public Health Service of Amsterdam. Primary endpoint: Anal HPV-16/18 DNA positivity prevalence. Started Feb 2023; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2022-502224-49-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502224-49-00.